Thoracoabdominal Artery Stent Graft System Exploratory Study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06710938, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Lifetech Scientific (Shenzhen) Co., Ltd.
- Trial code
- NCT06710938
- Record updated
- 26 May 2026
- Original description
This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).Read full original descriptionShow less
Exploratory Study of Thoracoabdominal Artery Stent Graft System in the Treatment of Thoracoabdominal Aortic Aneurysms
This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).
Inclusion: Age: 18 to 80 years old; Patients diagnosed with a Thoracoabdominal aortic aneurysm (based on the modified Crawford classification and European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms), and should meet at least ONE of the following conditions:; Maximum diameter of TAAA is >50 mm; TAAA diameter increases by more than 5 mm in the past 6 months or by more than 10 mm in the past 1 year; Definite symptoms associated with TAAA, such as abdominal pain and back pain; Anatomical Criteria; Proximal landing zone (aorta or implanted graft): the diameter ranges from 17 to 36 mm, and length should be ≥25 mm; Distal landing zone (aorta or implanted graft): If distal landing zone is in iliac artery, distal landing zone diameter ranges from 7 to 25 mm, and length should be ≥15 mm; If the distal landing zone is in the abdominal aorta, distal landing zone diameter ranges from 12 to 36 mm, and length should be ≥20 mm; Visceral branch landing zone: the diameter ranges from 6 to 13 mm, and the length should be ≥15 mm; Renal artery landing zone: the diameter ranges from 4.5 to 9 mm, and the length should be ≥15 mm; Appropriate iliac, femoral, and upper limb arterial access; Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol; Patients do not want to or cannot wait for the approved alternative.
Exclusion: Patients with ruptured thoracoabdominal aortic aneurysms in unstable hemodynamic condition; Patients with infected or mycotic thoracoabdominal aortic aneurysms; Patients with systemic or local infections that may increase the risk of endovascular graft infection; Patients with a history of acute coronary syndrome within the recent 6 months; Acute coronary syndrome refers to acute cardiac ischemic syndrome caused by rupture or erosion of unstable atherosclerotic plaques in the coronary artery and fresh thrombosis, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris; Patients with transient ischemic attack (TIA) or ischemic/hemorrhagic stroke within the recent 3 months; Patients with severe pulmonary insufficiency who cannot tolerate general anesthesia; Patients with abnormal liver and kidney function before operation [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal value; Serum creatinine (Cr) >150umol/L]; Patients with thoracoabdominal aortic dissection; Patients with occluded superior mesenteric artery, celiac trunk artery, or renal artery; Patients requiring simultaneous coverage or embolization of bilateral internal iliac arteries; Patients with severe stenosis, calcification or mural thrombus at stent-graft landing zone, and this situation leads to difficulty in adhering the covered stent or affecting the patency of the stent.